{
    "title": "104_s1191",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as ``The Consumer Access to Prescription \nDrugs Act of 1995''.\n\nSEC. 2. APPROVAL AND MARKETING OF GENERIC DRUGS.\n\n    (a) Approval of Applications.--For purposes of acceptance and \nconsideration by the Secretary of an application under subsections (b), \n(c), and (j) of section 505, and subsections (b), (c), and (n) of \nsection 512, of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355 \n(b), (c), and (j), and 360b (b), (c), and (n)), the expiration date of \na patent that is the subject of a certification under section \n505(b)(2)(A) (ii), (iii), or (iv), section 505(j)(2)(A)(vii) (II), \n(III), or (IV), or section 512(n)(1)(H) (ii), (iii), or (iv), \nrespectively, made in an application submitted prior to June 8, 1995, \nor in an application submitted on or after that date in which the \napplicant certifies that substantial investment was made prior to June \n8, 1995, shall be deemed to be the date on which such patent would have \nexpired under the law in effect on the day preceding December 8, 1994.\n    (b) Right To Market.--The remedies of section 271(e)(4) of title \n35, United States Code, shall not apply to acts which--\n            (1) were commenced or for which a substantial investment \n        was made prior to June 8, 1995; and\n            (2) became infringing by reason of section 154(c)(1) of \n        such title, as amended by section 532 of the Uruguay Round \n        Agreements Act (Public Law 103-465; 108 Stat. 4983).\n    (c) Equitable Remuneration.--For acts described in subsection (b), \nequitable remuneration of the type described in section 154(c)(3) of \ntitle 35, United States Code, as amended by section 532 of the Uruguay \nRound Agreements Act (Public Law 103-465; 108 Stat. 4983) may be \nawarded to a patentee only if there has been--\n            (1) the commercial manufacture, use, offer to sell, or \n        sale, within the United States of an approved drug that is the \n        subject of an application described in subsection (a); or\n            (2) the importation into the United States of an approved \n        drug that is the subject of an application described in \n        subsection (a).\n\nSEC. 3. DEFINITIONS.\n\n    (a) Acts Which Were Commenced.--The submission of an application \nfor approval of a drug under section 505(b)(2), 505(j), 507, or 512(n), \nof the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355 (b)(2) and \n(j), 357, and 360b(n)) prior to June 8, 1995, or the subsequent making, \nusing, offering to sell, selling, or importing of the drug which is the \nsubject of the application, shall constitute acts which were commenced \nprior to June 8, 1995, as that term is used in this Act and in section \n154(c)(2) of title 35, United States Code, as amended by section 532 of \nthe Uruguay Round Agreements Act (Public Law 103-465; 108 Stat. 4983). \nA person who submits such application, and a person who supplied any \nactive ingredient used by such person in such drug, shall be deemed to \nhave performed acts which were commenced prior to June 8, 1995.\n    (b) Substantial Investment.--The development of a product \nformulation and the manufacture of an experimental batch of a drug that \nbecomes the subject of an application, or the initiation of stability \nor bioequivalency studies, by an applicant referred to in section \n505(b)(2), 505(j), or 512(n), or by a manufacturer of a drug referred \nto in section 507, of the Federal Food, Drug, and Cosmetic Act (21 \nU.S.C. 355 (b)(2) and (j), 360b(n), and 357) shall constitute \nsubstantial investment, as that term is used in this Act and in section \n154(c)(2)(A) of title 35, United States Code, as amended by section 532 \nof the Uruguay Round Agreements Act (Public Law 103-465; 108 Stat. \n4983). A person who supplied any active ingredient used by such \napplicant in such drug or by such manufacturer in such drug shall be \ndeemed to have made substantial investment by having supplied the \nactive ingredient to such applicant or such manufacturer.\n\nSEC. 4. APPLICABILITY.\n\n    (a) Applicability to Approval of Applications.--The provisions of \nthis Act shall govern--\n            (1) the approval or the effective date of approval of \n        applications under section 505(b)(2), 505(j), 507, or 512(n), \n        of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355 \n        (b)(2) and (j), 357, and 360b(n)) submitted on or after the \n        date of enactment of this Act; and\n            (2) the approval or effective date of approval of all \n        pending applications that have not received final approval as \n        of the date of enactment of this Act.\n    (b) Applicability in Judicial Proceedings.--The provisions of this \nAct shall apply in any action that--\n            (1) relates to the approval or marketing of a drug or the \n        infringement of a patent; and\n            (2)(A) is brought in a Federal or State court on or after \n        the date of enactment of this Act; or\n            (B) is brought in a Federal or State court prior to the \n        date of enactment of this Act and pending on such date."
}